Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Potentially Resectable Stage II/IIIa NSCLC
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Severance Hospital, Seoul, Seoul, South Korea